Clinical Trials Browser

OTHER × Hematologic Neoplasms × elotuzumab × Clear all

NCT02843074 2023-12-05

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Phase 2 Completed

53 enrolled 14 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms